argenx (ARGX) R&D Day 2024 summary

Strategic vision and future growth

• Vision 2030 targets 50,000 patients treated, 10 labeled indications, and 5 new molecules in phase 3 by 2030, building on a proven innovation and execution model.

• Expansion plans include consistent annual indication launches, two additional molecule launches before 2030, and a disciplined approach to scaling commercial operations.

• The company leverages a co-creation model with academic partners, physicians, and patients to identify novel targets and design patient-centric clinical trials.

• Commercial strategy is structured in three waves: maximizing MG and CIDP, expanding into neuromuscular (MMN), and broadening into other autoimmune indications like Sjögren's and Thyroid Eye Disease.

• Market leadership in MG and CIDP is expected to drive significant revenue growth, with a playbook focused on evidence generation, patient empowerment, and rapid global expansion.

Pipeline and innovation highlights

• FcRn leadership is extended with new molecules: ARGX-213 (monthly dosing, long half-life) and ARGX-121 (IgA sweeping antibody), both entering phase 1 in the next year.

• Empasiprubart (ARGX-117) is advanced as a phase 3 asset in MMN, CIDP, delayed graft function, and dermatomyositis, showing strong efficacy and safety in MMN phase 2.

• Efgartigimod (VYVGART) is approved in three indications, with label expansions underway for seronegative and ocular MG, and ongoing studies in myositis and Sjögren's.

• The innovation engine is supported by a robust patent portfolio, advanced antibody engineering, and a focus on precision tools targeting disease-driving biology.

• The company is committed to operationally seamless, adaptive trial designs to accelerate development and maximize data utility.

Clinical and commercial execution

• VYVGART achieved blockbuster status in MG, with rapid global launches and over 10,000 patients treated; CIDP launch is underway with strong early adoption.

• The addressable MG market is now estimated at up to 60,000 patients, driven by label expansions and earlier-line use, with similar market expansion expected in CIDP and MMN.

• Empasiprubart demonstrated 84–91% reduction in IVIG retreatment risk and significant functional improvement in MMN, supporting its move to phase 3 and potential first-line use.

• The company is leveraging its neurology relationships and patient engagement strategies to accelerate diagnosis and market development in rare neuromuscular diseases.

• Future growth includes expansion into more prevalent autoimmune diseases, with a focus on data-driven indication selection and combination strategies as biology understanding deepens.